First published 9/28/2026, 4:19:15 AM · Last updated 9/28/2026, 4:19:30 AM

Exploratory Signal Detection of Arrhythmia Reports for Empagliflozin, Sitagliptin, and Linagliptin in the Korea Adverse Event Reporting System

A journal article reports exploratory signal detection of arrhythmia reports associated with empagliflozin, sitagliptin, and linagliptin using the Korea Adverse Event Reporting System. Publisher listed as Drug Targets and Therapeutics (Pharmaceutical Society of Korea) with publication date 2026-09-30.

Categories: public-health, science-and-space

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 6/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 4/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 3/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 3/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 2/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 2/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

The article presents an analysis of arrhythmia adverse-event reports for three medications within Korea's national reporting database.

Location

Sources

Exploratory Signal Detection of Arrhythmia Reports for Empagliflozin, Sitagliptin, and Linagliptin in the Korea Adverse Event Reporting System

Report an issue